SI1915349T1 - Postopek za pripravo čistega amorfnega rosuvastatin kalcija - Google Patents
Postopek za pripravo čistega amorfnega rosuvastatin kalcijaInfo
- Publication number
- SI1915349T1 SI1915349T1 SI200632034A SI200632034A SI1915349T1 SI 1915349 T1 SI1915349 T1 SI 1915349T1 SI 200632034 A SI200632034 A SI 200632034A SI 200632034 A SI200632034 A SI 200632034A SI 1915349 T1 SI1915349 T1 SI 1915349T1
- Authority
- SI
- Slovenia
- Prior art keywords
- rosuvastatin calcium
- pure amorphous
- preparing pure
- amorphous rosuvastatin
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200500187 | 2005-06-24 | ||
EP06754502.0A EP1915349B2 (en) | 2005-06-24 | 2006-06-22 | Process for preparing pure amorphous rosuvastatin calcium |
PCT/EP2006/006008 WO2006136408A2 (en) | 2005-06-24 | 2006-06-22 | Process for preparing pure amorphous rosuvastatin calcium |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1915349T1 true SI1915349T1 (sl) | 2016-05-31 |
Family
ID=37440674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632034A SI1915349T1 (sl) | 2005-06-24 | 2006-06-22 | Postopek za pripravo čistega amorfnega rosuvastatin kalcija |
Country Status (12)
Country | Link |
---|---|
US (1) | US8207333B2 (sl) |
EP (1) | EP1915349B2 (sl) |
JP (1) | JP5416403B2 (sl) |
CN (1) | CN101203496B (sl) |
AU (1) | AU2006261088B2 (sl) |
CA (1) | CA2611920C (sl) |
ES (1) | ES2564807T5 (sl) |
HU (1) | HUE027012T2 (sl) |
IL (1) | IL187578A0 (sl) |
PL (1) | PL1915349T5 (sl) |
SI (1) | SI1915349T1 (sl) |
WO (1) | WO2006136408A2 (sl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1562912A2 (en) | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
CA2546701C (en) | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
ATE507209T1 (de) | 2003-12-02 | 2011-05-15 | Teva Pharma | Referenzstandard zur charakterisierung von rosuvastatin |
EP1737829A2 (en) | 2005-02-22 | 2007-01-03 | Teva Pharmaceutical Industries Ltd | Preparation of rosuvastatin |
JP5146965B2 (ja) * | 2005-06-24 | 2013-02-20 | レツク・フアーマシユーテイカルズ・デー・デー | 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法 |
JP2008515931A (ja) | 2005-08-16 | 2008-05-15 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶形ロスバスタチン中間体 |
EP1948618A1 (en) * | 2006-09-18 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
US8318933B2 (en) * | 2006-10-31 | 2012-11-27 | Aurobindo Pharma Ltd | Process for preparing rosuvastatin calcium |
ATE553098T1 (de) * | 2007-02-08 | 2012-04-15 | Aurobindo Pharma Ltd | Verfahren zur herstellung von rosuvastatin- calcium |
US7884226B2 (en) | 2007-07-12 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Purification of rosuvatatin intermediate by thin film evaporation and chemical method |
US8653265B2 (en) | 2008-05-27 | 2014-02-18 | Changzhou Pharmaceutical Factory | Preparation method of rosuvastatin calcium and its intermediates |
WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
EA019995B1 (ru) * | 2009-01-14 | 2014-07-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Соль розувастатина, способ ее получения и способ получения фармацевтически приемлемой соли розувастатина |
MX2011007478A (es) * | 2009-01-15 | 2011-09-15 | Sag Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsa | Proceso para la preparacion de sales de rosuvastatina. |
WO2011021058A1 (en) | 2009-08-17 | 2011-02-24 | Aurobindo Pharma Limited | Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester |
HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
FR2970178B1 (fr) * | 2011-01-07 | 2014-06-20 | Liliane Therese Jacquot | Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance |
CN102070537B (zh) * | 2011-01-28 | 2012-01-11 | 海南美大制药有限公司 | 一种瑞舒伐他汀钙化合物及其新制法 |
WO2013046222A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | A process for the preparation of amorphous rosuvastatin calcium |
CN103709107B (zh) * | 2012-09-29 | 2016-04-20 | 安徽省庆云医药化工有限公司 | 瑞舒伐他汀甲酯的新晶型及其制备方法 |
CN104370827B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 瑞舒伐他汀钙化合物 |
AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
US11970482B2 (en) * | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
CN108398501A (zh) * | 2018-03-02 | 2018-08-14 | 海南通用三洋药业有限公司 | 一种检测瑞舒伐他汀钙有关物质的方法 |
CN108675931A (zh) * | 2018-05-18 | 2018-10-19 | 合肥合源药业有限公司 | 一种低钡他汀钙及其制备方法 |
CN111170950A (zh) * | 2020-01-16 | 2020-05-19 | 河南豫辰药业股份有限公司 | 一种瑞舒伐他汀钙盐的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
EP1562912A2 (en) * | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
EP1678148A1 (en) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
WO2005054207A1 (en) | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
WO2005077917A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
EP1797046A2 (en) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
-
2006
- 2006-06-22 US US11/916,599 patent/US8207333B2/en active Active
- 2006-06-22 JP JP2008517414A patent/JP5416403B2/ja not_active Expired - Fee Related
- 2006-06-22 PL PL06754502T patent/PL1915349T5/pl unknown
- 2006-06-22 CN CN2006800226730A patent/CN101203496B/zh not_active Expired - Fee Related
- 2006-06-22 AU AU2006261088A patent/AU2006261088B2/en not_active Ceased
- 2006-06-22 SI SI200632034A patent/SI1915349T1/sl unknown
- 2006-06-22 WO PCT/EP2006/006008 patent/WO2006136408A2/en active Application Filing
- 2006-06-22 EP EP06754502.0A patent/EP1915349B2/en not_active Not-in-force
- 2006-06-22 HU HUE06754502A patent/HUE027012T2/en unknown
- 2006-06-22 ES ES06754502T patent/ES2564807T5/es active Active
- 2006-06-22 CA CA2611920A patent/CA2611920C/en not_active Expired - Fee Related
-
2007
- 2007-11-22 IL IL187578A patent/IL187578A0/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
HUE027012T2 (en) | 2016-10-28 |
ES2564807T5 (es) | 2019-02-26 |
WO2006136408A3 (en) | 2007-04-19 |
AU2006261088A1 (en) | 2006-12-28 |
EP1915349A2 (en) | 2008-04-30 |
EP1915349B1 (en) | 2015-12-09 |
US20080188504A1 (en) | 2008-08-07 |
IL187578A0 (en) | 2008-03-20 |
CA2611920A1 (en) | 2006-12-28 |
PL1915349T3 (pl) | 2016-05-31 |
CN101203496B (zh) | 2011-04-20 |
WO2006136408A2 (en) | 2006-12-28 |
PL1915349T5 (pl) | 2019-02-28 |
CN101203496A (zh) | 2008-06-18 |
CA2611920C (en) | 2015-05-05 |
US8207333B2 (en) | 2012-06-26 |
ES2564807T3 (es) | 2016-03-29 |
JP2008543899A (ja) | 2008-12-04 |
AU2006261088B2 (en) | 2012-11-08 |
EP1915349B2 (en) | 2018-09-12 |
JP5416403B2 (ja) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL187578A0 (en) | Process for preparing pure amorphous rosuvastatin calcium | |
IL187483A0 (en) | Process for preparing amorphous rosuvastatin calcium free of impurities | |
IL183528A0 (en) | Process for preparing rosuvastatin | |
PT1923359E (pt) | Processo para a produção de frasquinhos | |
SI1727795T1 (sl) | Postopek za pripravo atorvastatin kalcija v amorfni obliki | |
EP1813677A4 (en) | PROCESS FOR MAKING BASIC SUBSTANCE | |
EP1828170A4 (en) | PROCESS FOR PREPARING VORICONAZOLE | |
HK1119152A1 (en) | Process for producing nanocrystalline | |
ZA200608083B (en) | Process for preparing 5-methyl-2-furfural | |
EP1748076A4 (en) | PROCESS FOR THE MANUFACTURE OF HYDROXYCARBOXYLIC ACID | |
EP1852100A4 (en) | PROCESS FOR MANUFACTURING PELLETS | |
TWI372145B (en) | Process for preparing alkylanilides | |
IL182474A0 (en) | Process for forming amorphous atorvastatin | |
IL197327A0 (en) | Crystalline rosuvastatin calcium | |
EP1751123A4 (en) | PROCESS FOR PREPARING IRBESARTAN | |
IL183239A0 (en) | Process for preparing amorphous valsartan | |
IL185872A0 (en) | Process for preparing levetiracetam | |
EP1930484A4 (en) | PROCESS FOR PRODUCING MONOCRYSTAL | |
ZA200608632B (en) | Process for forming amorphous atorvastatin calcium | |
ZA200806049B (en) | Cefdinir synthesis process | |
EP1939301A4 (en) | PROCESS FOR PRODUCING A USEFUL SUBSTANCE | |
IL182211A0 (en) | Process for preparing purine compounds | |
EP1856101A4 (en) | PROCESS FOR PREPARING AMORPHENE SALTS | |
EP1907474A4 (en) | PROCESS FOR PRODUCING A POLYOLEFIN | |
EP1852518A4 (en) | METHOD FOR PRODUCING MULTIFUNCTIONAL MATERIAL |